Business Context and Reporting Period
This Form 8-K Current Report was filed by Exicure, Inc. on September 13, 2023. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Chicago, Illinois. Its common stock trades on The Nasdaq Capital Market under the symbol "XCUR".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses on regulatory compliance and legal contingencies rather than financial performance metrics.
Material Changes and Events
- Nasdaq Delisting Notice: The Company received notice from Nasdaq that its common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days, violating Listing Rule 5550(a)(2).
- Compliance Period: Exicure has been granted an initial 180-day compliance period ending March 11, 2024, to regain compliance. This requires the stock to close at $1.00 or more for 10 consecutive business days.
- License Termination: Northwestern University terminated the Company's 2015 Restated License Agreement on September 10, 2023, alleging a breach. The cure period for the 2014 License Agreement remains open until October 2, 2023.
Outlook, Risks, and Management Commentary
Management intends to monitor the stock price and consider options to achieve compliance, including effecting a reverse stock split if necessary. If the Company fails to regain compliance by the March 11, 2024 deadline and is ineligible for an additional period, the stock may be delisted. The Company may appeal a delisting determination to the Nasdaq Listing Qualifications Panel, though success is not assured. Regarding the legal dispute, the Company intends to continue discussions with Northwestern to seek a resolution and is exploring strategic alternatives to maximize stockholder value from its historical assets.
Investor Verification Checklist
- Verify the current closing bid price of XCUR stock to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor announcements regarding a potential reverse stock split to cure the listing deficiency.
- Track the status of the dispute with Northwestern University, specifically the outcome of the cure period for the 2014 License ending October 2, 2023.
- Review future filings for updates on strategic alternatives or asset sales mentioned by management.